These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 19940304

  • 1. Denosumab, osteoporosis, and prevention of fractures.
    Kiechl S, Willeit J, Schett G.
    N Engl J Med; 2009 Nov 26; 361(22):2188-9; author reply 2190-1. PubMed ID: 19940304
    [No Abstract] [Full Text] [Related]

  • 2. Denosumab, osteoporosis, and prevention of fractures.
    Kyrgidis A.
    N Engl J Med; 2009 Nov 26; 361(22):2189; author reply 2190-1. PubMed ID: 19950409
    [No Abstract] [Full Text] [Related]

  • 3. Denosumab (prolia) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2010 Oct 18; 52(1349):81-2. PubMed ID: 21045756
    [No Abstract] [Full Text] [Related]

  • 4. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM, Iranikhah MM, Wilborn TW.
    Pharmacotherapy; 2011 May 18; 31(5):510-23. PubMed ID: 21923432
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Denosumab, osteoporosis, and prevention of fractures.
    Blackwood J.
    N Engl J Med; 2009 Nov 26; 361(22):2189; author reply 2190-1. PubMed ID: 19950411
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
    Lewiecki EM.
    Curr Med Res Opin; 2010 Dec 26; 26(12):2807-12. PubMed ID: 21050058
    [Abstract] [Full Text] [Related]

  • 11. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial.
    N Engl J Med; 2009 Aug 20; 361(8):756-65. PubMed ID: 19671655
    [Abstract] [Full Text] [Related]

  • 12. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C.
    Med Monatsschr Pharm; 2010 Oct 20; 33(10):370-5. PubMed ID: 21072910
    [Abstract] [Full Text] [Related]

  • 13. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
    Prescrire Int; 2011 Jun 20; 20(117):145-8. PubMed ID: 21678700
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].
    Dimai HP, Pietschmann P, Resch H, Preisinger E, Fahrleitner-Pammer A, Dobnig H, Klaushofer K, Austrian Society for Bone and Mineral Research (AuSBMR).
    Wien Med Wochenschr; 2010 Dec 20; 160(21-22):586-9. PubMed ID: 21170699
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA, AMG 162 Bone Loss Study Group.
    J Bone Miner Res; 2007 Dec 20; 22(12):1832-41. PubMed ID: 17708711
    [Abstract] [Full Text] [Related]

  • 20. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis.
    von Keyserlingk C, Hopkins R, Anastasilakis A, Toulis K, Goeree R, Tarride JE, Xie F.
    Semin Arthritis Rheum; 2011 Oct 20; 41(2):178-86. PubMed ID: 21616520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.